HOPE’s overall results fell short, yet points to questions about whether Cognito’s Spectris device may merit further study in early Alzheimer’s disease, as detailed in the HOPE study report. The 12-month pivotal trial did not meet its primary endpoint among participants with mild-to-moderate disease, while a prespecified mild subgroup showed results favoring the device on several measures.
Cognito presented the findings at the Clinical Trials on Alzheimer’s Disease conference. The randomized, double-blind, sham-controlled study enrolled 673 participants, who received active Spectris therapy or sham through daily, one-hour sessions at home.
Yet Points to a Subgroup Signal, Not Overall Success
The primary analysis included 663 participants. At month 12, the integrated Alzheimer’s Disease MMSE and ADCS-ADL Rating Scale did not differ between the active and sham groups. Secondary endpoints in the overall population also showed no statistically significant differences.

A prespecified analysis found that treatment effects differed between mild and moderate participants. In the mild subgroup of 395 people, results consistently favored Spectris across all five clinical measures evaluated at month 12. The subgroup findings do not change the primary result for the full study population.
Within that mild subgroup, the company reported 56% slowing of decline on the ADCS-ADL daily-function measure, with nominal p=0.016. It reported 47% slowing on the CDR-SB measure of cognition and function, with nominal p=0.004, compared with sham at 12 months. These are subgroup estimates, and the reported p-values are nominal.
The source described estimated differences corresponding to 5.3 months of delay in daily-function decline and 5.6 months in cognition and function over the study. It said these time-saved estimates were exploratory and derived from differences between decline curves.
Exploratory Measures Add Context
Additional analyses used the What Matters Most framework, developed through research with people living with Alzheimer’s disease and care partners. In the mild subgroup analysis, the framework showed a 60% slowing of decline on its composite score, with nominal p=0.04. The company said this exploratory measure covers everyday-life domains identified as meaningful to affected people.
In a separate prespecified per-protocol analysis of mild participants meeting treatment-use criteria, the reported composite estimate was 86% slowing of decline. That analysis included 169 participants. The source cautioned that per-protocol comparisons may reflect differences between people who did and did not meet the criteria, and do not establish that adherence caused treatment benefit.
Those findings sit within a broader discussion of how digital tools are evaluated in health research. Meditech Wire has also covered a patient-device conversation test and an Apple study of health chatbots, which examine different technologies and questions.
Safety and Regulatory Steps Remain
Cognito reported no unanticipated adverse device effects in either study arm. Adverse device effects were reported in 18.3% of participants receiving active treatment and 15.5% receiving sham. The source listed headache, tinnitus, fatigue, dizziness, hallucination, seizure and ear pain among effects reported in more than 1% of participants.
The company said it plans to work with the FDA on the evidence and regulatory requirements for a de novo authorization submission. Spectris AD has received FDA breakthrough device designation, but the designation does not establish authorization. Cognito also plans to continue following longer-term treatment experience through the HOPE open-label extension.
The next step described by the company is discussion with the FDA. Any interpretation of the mild subgroup results will need to account for the unsuccessful overall primary endpoint and the exploratory nature of some analyses. For now, HOPE offers a signal for further evaluation, not evidence of established benefit across the full study population.

